Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 5797930, 8 pages
http://dx.doi.org/10.1155/2016/5797930
Clinical Study

Macrophage Migration Inhibitory Factor and Malondialdehyde as Potential Predictors of Vascular Risk Complications in Type 2 Diabetes Mellitus: Cross-Sectional Case Control Study in Saudi Arabia

1Medical Biochemistry Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
2Laboratory Medicine Department, College of Applied Medical Science, Umm Al Qura University, Makkah 21955, Saudi Arabia
3Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt
4Clinical Pathology Department, Al Azhar University, Cairo 11651, Egypt
5Clinical Chemistry Department, Al Noor Specialist Hospital, Makkah 21955, Saudi Arabia
6Cancer Epidemiology and Biostatistics Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt
7Kuwait Cancer Registry, 70653 Kuwait, Kuwait

Received 28 December 2015; Revised 10 April 2016; Accepted 20 April 2016

Academic Editor: Dianne Cooper

Copyright © 2016 Heba Kamal Morsi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, 2015, http://www.who.int/diabetes/en.
  2. International Diabetes Federation, IDF Diabetes Atlas, International Diabetes Federation, Brussels, Belgium, 7th edition, 2015, http://www.diabetesatlas.org.
  3. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 36, supplement 1, pp. s67–s74, 2013. View at Publisher · View at Google Scholar
  4. Statistical Book Year, Saudi Arabia, Riyadh: Ministry of Finance. 1992 and 2010; Chapter 11: Health Budget: 106–133.
  5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, “Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Google Scholar
  6. C. J. Packard, I. Ford, M. Robertson et al., “Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER),” Circulation, vol. 112, no. 20, pp. 3058–3065, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. S. R. Khan, N. Ayub, S. Nawab, and T. S. Shamsi, “Triglyceride profile in dyslipidaemia of Type 2 diabetes mellitus,” Journal of the College of Physicians and Surgeons Pakistan, vol. 18, no. 5, pp. 270–273, 2008. View at Google Scholar
  8. B. Halliwell, “Free radicals and antioxidant—quo vadis?” Trends in Pharmacological Sciences, vol. 32, no. 3, pp. 125–130, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Kayankarnna, D. Thessomboon, S. Niyomtam, P. Pingmuangkaew, P. Nunthawarasilp, and S. Tangvarasittichai, “Elevated cadmium exposure associated with oxidative stress and oxidative DNA damage in population of cadmium-contaminated area,” International Journal of Toxicological and Pharmacological Research, vol. 5, no. 4, pp. 102–108, 2013. View at Google Scholar · View at Scopus
  10. M. Jaganjac, O. Tirosh, G. Cohen, S. Sasson, and N. Zarkovic, “Reactive aldehydes—second messengers of free radicals in diabetes mellitus,” Free Radical Research, vol. 47, no. 1, pp. 39–48, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Flaster, J. Bernhagen, T. Calandra, and R. Bucala, “The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity,” Molecular Endocrinology, vol. 21, no. 6, pp. 1267–1280, 2007. View at Publisher · View at Google Scholar
  12. H. Lue, R. Kleemann, T. Calandra, T. Roger, and J. Bernhagen, “Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease,” Microbes and Infection, vol. 4, no. 4, pp. 449–460, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Bernhagen, R. Krohn, H. Lue et al., “MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment,” Nature Medicine, vol. 13, no. 5, pp. 587–596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Y. Hoi, M. N. Iskander, and E. F. Morand, “Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases,” Inflammation and Allergy—Drug Targets, vol. 6, no. 3, pp. 183–190, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Verschuren, T. Kooistra, J. Bernhagen et al., “MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease,” Circulation Research, vol. 105, no. 1, pp. 99–107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Stosic-Grujicic, I. Stojanovic, D. Maksimovic-Ivanic et al., “Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus,” Journal of Cellular Physiology, vol. 215, no. 3, pp. 665–675, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. N. G. Cruz, L. P. Sousa, M. O. Sousa, N. T. Pietrani, A. P. Fernandes, and K. B. Gomes, “The linkage between inflammation and Type 2 diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 99, no. 2, pp. 85–92, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Tran, S. Oliver, J. Rosa, and P. Galassetti, “Aspects of inflammation and oxidative stress in pediatric obesity and type 1 diabetes: an overview of ten years of studies,” Experimental Diabetes Research, vol. 2012, Article ID 683680, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. J. A. Ehses, M. Böni-Schnetzler, M. Faulenbach, and M. Y. Donath, “Macrophages, cytokines and β-cell death in Type 2 diabetes,” Biochemical Society Transactions, vol. 36, no. 3, pp. 340–342, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. I. Sánchez-Zamora and M. Rodriguez-Sosa, “The role of MIF in type 1 and type 2 diabetes mellitus,” Journal of Diabetes Research, vol. 2014, Article ID 804519, 6 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. K. G. Alberti and P. Z. Zimmet, “Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation,” Diabetic Medicine, vol. 15, no. 7, pp. 539–553, 1999. View at Google Scholar
  22. The International Expert Committee, “International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes,” Diabetes Care, vol. 32, no. 7, pp. 1327–1334, 2009. View at Publisher · View at Google Scholar
  23. H. Ohkawa, N. Ohishi, and K. Yagi, “Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction,” Analytical Biochemistry, vol. 95, no. 2, pp. 351–358, 1979. View at Publisher · View at Google Scholar · View at Scopus
  24. B. K. Tiwari, K. B. Pandey, B. A. Abidi, and S. I. Rizvi, “Markers of oxidative stress during diabetes mellitus,” Journal of Biomarkers, vol. 2013, Article ID 378790, 8 pages, 2013. View at Publisher · View at Google Scholar
  25. G. Bonfanti, R. B. Ceolin, T. Valcorte et al., “δ-Aminolevulinate dehydratase activity in type 2 diabetic patients and its association with lipid profile and oxidative stress,” Clinical Biochemistry, vol. 44, no. 13, pp. 1105–1109, 2011. View at Publisher · View at Google Scholar
  26. P. Moriel, F. L. Plavnik, M. T. Zanella, M. C. Bertolami, and D. S. P. Abdalla, “Lipid peroxidation and antioxidants in hyperlipidemia and hypertension,” Biological Research, vol. 33, no. 2, pp. 105–112, 2000. View at Google Scholar · View at Scopus
  27. A. D. Mooradian, “Dyslipidemia in type 2 diabetes mellitus,” Nature Clinical Practice Endocrinology & Metabolism, vol. 5, no. 3, pp. 150–159, 2009. View at Publisher · View at Google Scholar
  28. T. Hayek, K. Hussein, M. Aviram et al., “Macrophage-foam cell formation in streptozotocin-induced diabetic mice: stimulatory effect of glucose,” Atherosclerosis, vol. 183, no. 1, pp. 25–33, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. M. O. Ebesunun and O. Adedipe, “Glycated haemoglobin, lipids and drug adherence in Type 2 diabetes mellitus: experience in high income group,” Journal of Medicine and Medical Sciences, vol. 2, no. 1, pp. 642–647, 2011. View at Google Scholar
  30. O. M. Finucane, C. M. Reynolds, F. C. McGillicuddy, and H. M. Roche, “Insights into the role of macrophage migration inhibitory factor in obesity and insulin resistance,” Proceedings of the Nutrition Society, vol. 71, no. 4, pp. 622–633, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Makino, T. Nakamura, M. Hirano et al., “High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus,” Atherosclerosis, vol. 213, no. 2, pp. 573–578, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Atsumi, Y.-R. Cho, L. Leng et al., “The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation,” The Journal of Immunology, vol. 179, no. 8, pp. 5399–5406, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. E. J. Miller, J. Li, L. Leng et al., “Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart,” Nature, vol. 451, no. 7178, pp. 578–582, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Saksida, S. Stosic-Grujicic, and I. Stojanovic, “The role of macrophage migration inhibitory factor in obesity-associated type 2 diabetes in mice,” Archives of Biological Sciences, vol. 65, no. 2, pp. 499–505, 2013. View at Publisher · View at Google Scholar
  35. I. Stojanovic, T. Saksida, I. Nikolic, F. Nicoletti, and S. Stosic-Grujicic, “Macrophage migration inhibitory factor deficiency protects pancreatic islets from cytokine-induced apoptosis in vitro,” Clinical and Experimental Immunology, vol. 169, no. 2, pp. 156–163, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. D. M. Muoio and C. B. Newgard, “Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes,” Nature Reviews Molecular Cell Biology, vol. 9, no. 3, pp. 193–205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Zhang, T. M. Dall, S. E. Mann et al., “The economic costs of undiagnosed diabetes,” Population Health Management, vol. 12, no. 2, pp. 95–101, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Sanchez-Zamora, L. I. Terrazas, A. Vilches-Flores et al., “Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus,” The FASEB Journal, vol. 24, no. 7, pp. 2583–2590, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Kleemann and R. Bucala, “Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities,” Mediators of Inflammation, vol. 2010, Article ID 610479, 7 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. X. Y. Yu, H. M. Chen, J. L. Liang et al., “Hyperglycemic myocardial damage is mediated by proinflammatory cytokine: macrophage migration inhibitory factor,” PLoS ONE, vol. 6, no. 1, Article ID e16239, 2011. View at Publisher · View at Google Scholar
  41. M. Akyildiz, F. Gunsar, D. Nart et al., “Macrophage migration inhibitory factor expression and MIF gene −173 G/C polymorphism in nonalcoholic fatty liver disease,” European Journal of Gastroenterology and Hepatology, vol. 22, no. 2, pp. 192–198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. E. H. Harris, “Elevated liver function tests in type 2 diabetes,” Clinical Diabetes, vol. 23, no. 3, pp. 115–119, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Bruchfeld, J. J. Carrero, A. R. Qureshi et al., “Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation,” Molecular Medicine, vol. 15, no. 3-4, pp. 70–75, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Caputo, A. Mokhtari, A. Miceli et al., “Controlled reoxygenation during cardiopulmonary bypass decreases markers of organ damage, inflammation, and oxidative stress in single-ventricle patients undergoing pediatric heart surgery,” The Journal of Thoracic and Cardiovascular Surgery, vol. 148, no. 3, pp. 792–801.e8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Dhanantwari, S. Nadaraj, A. Kenessey et al., “Macrophage migration inhibitory factor induces cardiomyocyte apoptosis,” Biochemical and Biophysical Research Communications, vol. 371, no. 2, pp. 298–303, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Tripathy, P. Mohanty, S. Dhindsa et al., “Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects,” Diabetes, vol. 52, no. 12, pp. 2882–2887, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. M. D. Bikkad, S. D. Somwanshi, S. H. Ghuge, and N. S. Nagane, “Oxidative stress in type II diabetes mellitus,” Biomedical Research, vol. 25, no. 1, pp. 84–87, 2014. View at Google Scholar · View at Scopus
  48. S. A. Shinde, A. D. Deshmukh, A. N. Suryakar, U. K. More, and M. A. Tilak, “The level of oxidative stress and antioxidants in diabetes mellitus before and after diabetic treatment with or without antioxidants,” Indian Journal of Basic and Applied Medical Research, vol. 3, no. 2, pp. 455–460, 2014. View at Google Scholar
  49. S. M. Manohar, S. R. Vaikasuvu, K. Deepthi, A. Sachan, and S. R. P. V. L. Narasimha, “An association of hyperglycemia with plasma malondialdehyde and atherogenic lipid risk factors in newly diagnosed Type 2 diabetic patients,” Journal of Research in Medical Sciences, vol. 18, no. 2, pp. 89–93, 2013. View at Google Scholar · View at Scopus
  50. N. Tirkey, S. Pilkhwal, A. Kuhad, and K. Chopra, “Hesperidin, a citrus bioflavonoid, decreases the oxidative stress produced by carbon tetrachloride in rat liver and kidney,” BMC Pharmacology, vol. 5, article 2, 2005. View at Google Scholar
  51. P. H. Whiting, A. Kalansooriya, I. Holbrook, F. Haddad, and P. E. Jennings, “The relationship between chronic glycaemic control and oxidative stress in type 2 diabetes mellitus,” British Journal of Biomedical Science, vol. 65, no. 2, pp. 71–74, 2008. View at Google Scholar · View at Scopus
  52. J. C. Jennette, J. L. Oslon, M. M. Schwartz, and F. G. Silva, Heptinstall's Pathology of Kidney, vol. 1, Lippincots Williams & Wilkins, Philadelphia, Pa, USA, 6th edition, 2007.
  53. A. Y. Andreyev, Y. E. Kushnareva, and A. A. Starkov, “Mitochondrial metabolism of reactive oxygen species,” Biochemistry, vol. 70, no. 2, pp. 200–214, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. F. Giacco and M. Brownlee, “Oxidative stress and diabetic complications,” Circulation Research, vol. 107, no. 9, pp. 1058–1070, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. A. C. Maritim, R. A. Sanders, and J. B. Watkins, “Diabetes, oxidative stress, and antioxidants: a review,” Journal of Biochemical and Molecular Toxicology, vol. 17, no. 1, pp. 24–38, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. S. D. M. Bandeira, L. J. S. da Fonseca, G. D. S. Guedes, L. A. Rabelo, M. O. F. Goulart, and S. M. L. Vasconcelos, “Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus,” International Journal of Molecular Sciences, vol. 14, no. 2, pp. 3265–3284, 2013. View at Publisher · View at Google Scholar · View at Scopus